Literature DB >> 24509736

Imbruvica--next big drug in B-cell cancer--approved by FDA.

Malini Guha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24509736     DOI： 10.1038/nbt0214-113

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Companies in rapid pursuit of Btk immunokinase.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2012-03-07       Impact factor: 54.908

2.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

3.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
  3 in total
  5 in total

1.  Lilly pays $50 million for Korean BTK.

Authors:  Allison Proffitt
Journal:  Nat Biotechnol       Date:  2015-05       Impact factor: 54.908

2.  Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.

Authors:  Yanhua Zhou; Hongtao Lu; Meifeng Yang; Chenhong Xu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

3.  Novel drug-target interactions via link prediction and network embedding.

Authors:  E Amiri Souri; R Laddach; S N Karagiannis; L G Papageorgiou; S Tsoka
Journal:  BMC Bioinformatics       Date:  2022-04-04       Impact factor: 3.169

4.  New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.

Authors:  Andreea Lucia Stancu; Mitchell R Smith; Alexandru Almasan
Journal:  Discoveries (Craiova)       Date:  2014 Jan-Mar

5.  A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation.

Authors:  E Grassilli; F Pisano; A Cialdella; S Bonomo; C Missaglia; M G Cerrito; L Masiero; L Ianzano; F Giordano; V Cicirelli; R Narloch; F D'Amato; B Noli; G L Ferri; B E Leone; G Stanta; S Bonin; K Helin; R Giovannoni; M Lavitrano
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.